MX2020005006A - Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. - Google Patents

Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.

Info

Publication number
MX2020005006A
MX2020005006A MX2020005006A MX2020005006A MX2020005006A MX 2020005006 A MX2020005006 A MX 2020005006A MX 2020005006 A MX2020005006 A MX 2020005006A MX 2020005006 A MX2020005006 A MX 2020005006A MX 2020005006 A MX2020005006 A MX 2020005006A
Authority
MX
Mexico
Prior art keywords
cell proliferative
proliferative disorder
prophylaxis
therapy
medicament
Prior art date
Application number
MX2020005006A
Other languages
English (en)
Inventor
Udai Banerji
Original Assignee
The Institute Of Cancer Res Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute Of Cancer Res Royal Cancer Hospital filed Critical The Institute Of Cancer Res Royal Cancer Hospital
Publication of MX2020005006A publication Critical patent/MX2020005006A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un medicamento para el tratamiento o prevención de un trastorno proliferativo celular, comprendiendo el medicamento como ingrediente activo un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo, en donde el medicamento se usa de tal manera que: (a) tal compuesto o sal se administra dos veces por semana durante 3 semanas, (b) la administración de tal compuesto o sal se detiene durante la siguiente semana, y (c) las etapas (a) y (b) se repiten posteriormente por lo menos una vez.
MX2020005006A 2017-11-16 2018-05-16 Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. MX2020005006A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/079506 WO2019096397A1 (en) 2017-11-16 2017-11-16 Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
PCT/EP2018/062805 WO2019096449A1 (en) 2017-11-16 2018-05-16 Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder

Publications (1)

Publication Number Publication Date
MX2020005006A true MX2020005006A (es) 2020-10-12

Family

ID=60331633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005006A MX2020005006A (es) 2017-11-16 2018-05-16 Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.

Country Status (14)

Country Link
US (2) US11400090B2 (es)
EP (2) EP4364807A2 (es)
CN (1) CN111542317A (es)
AU (1) AU2018369325A1 (es)
BR (1) BR112020009452A2 (es)
CA (1) CA3082619A1 (es)
DK (1) DK3709996T3 (es)
FI (1) FI3709996T3 (es)
MX (1) MX2020005006A (es)
PT (1) PT3709996T (es)
RU (1) RU2760006C1 (es)
SG (1) SG11202004376TA (es)
TW (1) TWI795405B (es)
WO (2) WO2019096397A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US11873296B2 (en) * 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) * 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
EP2172198B1 (en) 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha p27 PROTEIN INDUCER
WO2013035754A1 (ja) 2011-09-05 2013-03-14 中外製薬株式会社 クマリン誘導体の製造方法

Also Published As

Publication number Publication date
WO2019096397A1 (en) 2019-05-23
BR112020009452A2 (pt) 2020-12-22
TW201922254A (zh) 2019-06-16
AU2018369325A1 (en) 2020-06-18
US11400090B2 (en) 2022-08-02
US20210330670A1 (en) 2021-10-28
SG11202004376TA (en) 2020-06-29
EP3709996B1 (en) 2024-02-28
US20230012116A1 (en) 2023-01-12
RU2760006C1 (ru) 2021-11-22
KR20200096538A (ko) 2020-08-12
PT3709996T (pt) 2024-04-15
EP3709996A1 (en) 2020-09-23
FI3709996T3 (fi) 2024-03-22
TWI795405B (zh) 2023-03-11
EP4364807A2 (en) 2024-05-08
CA3082619A1 (en) 2019-05-23
CN111542317A (zh) 2020-08-14
DK3709996T3 (da) 2024-03-11
WO2019096449A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2019012884A (es) Terapia de combinacion.
MY189601A (en) Treatment of beta-thalassemia using actrii ligand traps
PH12020550341A1 (en) Niraparib formulations
EA201992722A1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
NZ766454A (en) Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
IL307992A (en) Parasitic formulations containing isoxazoline and methods for treating blepharitis
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
EA202191130A1 (ru) Фармацевтическая композиция для лечения апластической анемии
MX2020005006A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
NZ751972A (en) Treatment of prurigo nodularis
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12020551620A1 (en) Compositions for preventing or treating dry eye